Pfizer INC Form 4 insider transactions

Pfizer Chairman and CEO Albert Bourla acquired 911 phantom stock units through the company's deferred compensation plan.

Pfizer Chairman and CEO Albert Bourla acquired 21 phantom stock units through a deferred compensation plan, increasing his beneficial ownership to 759,049 units.

Pfizer Director Cyrus Taraporevala acquired 1,386.834 phantom stock units as deferred compensation, increasing his total beneficial ownership to 27,139.547 units.

Pfizer Director James C. Smith acquired 1,664.201 phantom stock units as deferred compensation, increasing his beneficial ownership to 170,424.763 units.

Pfizer Director James Quincey acquired 1,433.062 phantom stock units as deferred compensation, increasing his total beneficial ownership.

Pfizer Director Shantanu Narayen acquired 1,849.112 phantom stock units as deferred compensation, increasing his total beneficial ownership to 187,925.141 units.

Pfizer Director Joseph Echevarria acquired 1,710.429 phantom stock units as deferred compensation, increasing his beneficial ownership to 153,398.145 units.

Pfizer Director Mortimer J. Buckley acquired 1,386.834 phantom stock units as deferred compensation, increasing his total beneficial ownership to 16,704.585 units.

Pfizer Inc. Chairman and CEO Albert Bourla reported the acquisition of 1,630 phantom stock units as part of a deferred compensation plan.

Pfizer's SVP & Controller, Jennifer B. Damico, reported significant equity grants and a tax-related share disposition.

Pfizer's Chairman and CEO, Albert Bourla, was granted 708,666 Stock Appreciation Rights with an exercise price of $26.58, vesting on March 3, 2031.

Pfizer's President of Research & Development, Christoffel Boshoff, was granted 259,844 stock appreciation rights with an exercise price of $26.58.

Pfizer's Chief Financial Officer, David M. Denton, was granted 216,537 stock appreciation rights with an exercise price of $26.58, vesting on March 3, 2031.

Pfizer's Executive Vice President, Douglas M. Lankler, was granted 194,883 stock appreciation rights with an exercise price of $26.58, vesting over five years.

Pfizer's Executive Vice President, Aamir Malik, was granted 194,883 stock appreciation rights with an exercise price of $26.58, vesting on March 3, 2031.

Pfizer Executive Vice President Andrew Baum received a grant of 303,151 Stock Appreciation Rights, which will settle in common stock on March 3, 2031.

Pfizer Executive Vice President Lidia Fonseca was granted 82,284 Stock Appreciation Rights, exercisable at $26.58, vesting and settling on March 3, 2031.

Pfizer Executive Vice President Michael McDermott was granted 151,576 stock appreciation rights with an exercise price of $26.58, vesting over five years.

Pfizer Executive Vice President Payal Sahni was granted 108,268 stock appreciation rights with an exercise price of $26.58, vesting over five years.

Pfizer's Executive Vice President, Alexandre de Germay, was granted 194,883 stock appreciation rights with an exercise price of $26.58, vesting on March 3, 2031.

Pfizer's SVP & Controller, Jennifer B. Damico, disposed of 655 shares of common stock to cover tax obligations related to vested restricted stock units.

Pfizer Executive Vice President Payal Sahni reported the earn-out and exercise of 56,888 stock appreciation rights, resulting in a net change in her direct common stock holdings.

Pfizer Executive Vice President Douglas M. Lankler reported the exercise of stock appreciation rights and subsequent share adjustments for tax and exercise price obligations.

Pfizer's SVP & Controller, Jennifer B. Damico, settled 17,558 stock appreciation rights, resulting in a net beneficial ownership of 12,696 common shares.

Pfizer's Chairman and CEO, Albert Bourla, reported the exercise of stock appreciation rights and subsequent share dispositions for tax and exercise price obligations.

Pfizer Executive Vice President Lidia Fonseca reported the exercise of stock appreciation rights and subsequent share disposals for tax and exercise price coverage.

Pfizer Executive Vice President Michael McDermott reported a series of equity transactions, including the earn-out of stock appreciation rights and subsequent share dispositions for tax and exercise costs.

Pfizer's President of R&D, Christoffel Boshoff, received performance share awards and had shares withheld for tax obligations.

Pfizer's President of R&D, Christoffel Boshoff, reported a disposition of 816 common shares to cover tax liabilities upon the vesting of restricted stock units.

Pfizer's SVP & Controller, Jennifer B. Damico, disposed of 419 shares of common stock to cover tax obligations related to restricted stock unit vesting.